StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alnylam Pharmaceuticals (ALNY) PT Lowered to $182 at Piper Jaffray; 'Cash of $1.9B to Launch Patisiran & Advance Pipeline'
November 17, 2017 6:49 AM
Piper Jaffray lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $182.00 (from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Alnylam Pharma (ALNY) Commences Rolling Submission of New Drug Application FDA for Patisiran
November 16, 2017 7:08 AM